Summary of Enliven Therapeutics Conference Call Company Overview - **Company**: Enliven Therapeutics (NasdaqGS:ELVN) - **Focus**: Development of an ATP-competitive, highly selective BCR-ABL inhibitor for chronic myeloid leukemia (CML) treatment [5][4] Industry Context - **CML Treatment Landscape**: CML has evolved from a severe diagnosis to a manageable chronic condition due to the introduction of tyrosine kinase inhibitors (TKIs). New agents are being developed to improve tolerability, convenience, and efficacy [5][4]. Key Mechanism and Differentiation - **Mechanism of Action**: Enliven's drug targets the BCR-ABL fusion protein, differentiating itself from existing treatments like Novartis' Semblix (asciminib) by binding to the orthosteric site, which may address resistance issues seen with allosteric inhibitors [7][8]. - **Resistance Management**: The company anticipates a significant unmet need for patients who develop resistance to allosteric inhibitors, positioning their drug as a potential solution for this patient population [9][15]. Clinical Data and Efficacy - **Efficacy Data**: Enliven reported a 32% achievement of major molecular response (MMR) in heavily pretreated late-line patients, with over half previously treated with asciminib and 70% being refractory or resistant [10][12]. - **Comparison with Semblix**: Initial data suggests that Enliven's drug shows response rates similar to Semblix in a more challenging patient population, providing confidence as they move towards phase three trials [11][12]. Competitive Landscape - **TURN701 Comparison**: TURN701 recently reported a 64% MMR achievement. Enliven acknowledges the need for TURN701 to demonstrate statistically significant superiority to compete effectively against Semblix, which has a long history of safety and efficacy [13][14]. - **Resistance Mutations**: The emergence of new resistant mutations to allosteric inhibitors is expected to drive demand for Enliven's ATP-competitive inhibitor, as it has shown strong performance against these mutations in preclinical studies [21][22]. Tolerability and Quality of Life - **Tolerability Issues**: Tolerability is a critical factor in treatment decisions. Enliven's drug is expected to have a favorable tolerability profile compared to existing treatments, which may lead to better patient adherence [17][18]. - **Switching Behavior**: Patients may switch treatments due to tolerability issues, and Enliven's drug aims to minimize these adverse effects [19][20]. Future Plans and Pipeline - **Phase Three Study**: Enliven plans to initiate a phase three study next year, targeting 400-500 patients, focusing on second-line plus treatment [45][49]. - **New Indications**: The company is exploring non-oncology indications and may announce new assets in 2026 [50]. Financial Position - **Cash Position**: Enliven ended the last quarter with approximately $480 million in cash, providing a runway into the first half of 2029 to support ongoing and upcoming trials [52]. Conclusion - Enliven Therapeutics is positioned to address significant unmet needs in the CML treatment landscape with its innovative ATP-competitive inhibitor, backed by promising early clinical data and a strong financial position to support future growth and development [5][52].

Core Insights - The market has shown a willingness to engage with Enliven Therapeutics (ELVN) over the past few years, indicating potential interest in the company's developments [1]. Company Analysis - Enliven Therapeutics has been under observation for several years, suggesting that the company is in a phase of scrutiny and evaluation by analysts [1]. - The author possesses a PhD in biochemistry and has extensive experience in analyzing clinical trials and biotech companies, which adds credibility to the insights shared about Enliven Therapeutics [1]. Industry Context - The article emphasizes the importance of understanding the science behind biotech investments, highlighting the complexities and potential pitfalls in the industry [1].

Enliven Therapeutics, Inc. (ELVN) closed the last trading session at $22.07, gaining 3.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $41.38 indicates an 87.5% upside potential.The average comprises eight short-term price targets ranging from a low of $33.00 to a high of $52.00, with a standard deviation of $6.52. While the lowest estimate indicates an increase of 49.5% from th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Delaware 81-1523849 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 6200 Lookout ...

Exhibit 99.1 Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update Completed enrollment of the randomized Phase 1b cohorts of the ongoing ENABLE trial of ELVN-001 in CML Remains on track to initiate Phase 3 pivotal trial of ELVN-001 in 2026 Strong balance sheet with $478 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first half of 2029 BOULDER, Colo., Nov. 12, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. ...

Group 1 - Enliven Therapeutics, Inc. (ELVN) shares have increased by 0.8% over the past four weeks, closing at $19.92, with a mean price target of $41.13 indicating a potential upside of 106.5% [1] - The average of eight short-term price targets ranges from a low of $33.00 to a high of $52.00, with a standard deviation of $6.66, suggesting a potential increase of 65.7% to 161% from the current price [2] - Analysts show strong agreement in revising earnings estimates higher, with two estimates moving up in the last 30 days and the Zacks Consensus Estimate increasing by 8.8% [11][12] Group 2 - ELVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13] - The consensus price target, while not entirely reliable, suggests a positive direction for price movement, which could guide further research into the stock's fundamentals [14]

Core Viewpoint - Enliven Therapeutics, Inc. (ELVN) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - For the fiscal year ending December 2025, Enliven Therapeutics is expected to earn -$1.95 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 15.2% over the past three months [8]. Institutional Investor Influence - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4][5]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Enliven Therapeutics' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Core Viewpoint - Enliven Therapeutics, Inc. (ELVN) shows significant upside potential with a mean price target of $41.13, indicating a 102.4% increase from its current trading price of $20.32 [1][2]. Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $6.66, suggesting variability in analyst predictions. The lowest estimate is $33.00 (62.4% increase), while the highest is $52.00 (155.9% increase) [2]. - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding ELVN's earnings prospects, as evidenced by a positive trend in earnings estimate revisions. The Zacks Consensus Estimate for the current year has increased by 5.3% over the last 30 days, with two estimates moving higher and no negative revisions [11][12]. - ELVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside in the near term [13]. Caution on Price Targets - While price targets are often sought after by investors, they can be misleading. Empirical research suggests that price targets rarely indicate actual stock price movements, and analysts may set overly optimistic targets due to business incentives [7][8][10].

Core Insights - Enliven Therapeutics, Inc. announced the presentation of data from its ENABLE Phase 1a/1b clinical trial of ELVN-001 at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting [1] - The presentation will include both an oral and a poster session, showcasing the company's focus on chronic myeloid leukemia treatment [2] Company Overview - Enliven Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of small molecule therapeutics aimed at improving patient survival and overall well-being [3] - The company employs a precision oncology approach to address unmet medical needs, leveraging insights into clinically validated biological targets and innovative chemistry [3]

Financial Performance - The company reported total operating expenses of $28.584 million for the three months ended June 30, 2025, compared to $24.603 million for the same period in 2024, representing an increase of approximately 16.1%[142] - The net loss for the three months ended June 30, 2025, was $25.335 million, compared to a net loss of $19.950 million for the same period in 2024, reflecting an increase in losses of approximately 27%[142] - Total operating expenses for the six months ended June 30, 2025, were $60.3 million, compared to $50.6 million for the same period in 2024, reflecting a 19.5% increase[147] - The net loss for the six months ended June 30, 2025, was $53.9 million, compared to a net loss of $42.7 million in the same period of 2024, indicating a 26.2% increase in losses[147] - Other income decreased to $3.2 million for the three months ended June 30, 2025, down from $4.7 million in the same period of 2024, a decline of 31.9%[146] Research and Development - Research and development expenses were $21.491 million for the three months ended June 30, 2025, up from $18.826 million in 2024, indicating a year-over-year increase of about 8.9%[142] - The company is advancing its ELVN-001 program into Phase 3 initiation expected in 2026, while exploring strategic alternatives for the ELVN-002 program, which will not be developed beyond 2025[121] - The company plans to expand its pipeline of product candidates and continue to incur significant expenses associated with being a public company[140] - Research and development expenses increased to $21.5 million for the three months ended June 30, 2025, up from $18.8 million in the same period of 2024, representing a 14.3% increase[144] Cash and Capital - As of June 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $490.5 million, which is expected to fund operations for at least the next 12 months[125] - The company raised aggregate gross proceeds of $90.0 million from a private placement in March 2024 and $230.0 million from a public offering in June 2025[124] - The company plans to seek additional capital through equity or debt financings to support ongoing operations and product development[156] - Future capital requirements will depend on various factors, including the costs of research and development, regulatory review, and commercialization efforts[160] - Net cash provided by financing activities rose to $218.6 million in the first half of 2025, up from $92.1 million in 2024, driven by proceeds from the sale of common stock and pre-funded warrants[167][168] Expenses - General and administrative expenses increased to $7.093 million for the three months ended June 30, 2025, from $5.777 million in 2024, marking a rise of approximately 22.8%[142] - General and administrative expenses rose to $7.1 million for the three months ended June 30, 2025, compared to $5.8 million in the same period of 2024, marking a 22.4% increase[145] - Net cash used in operating activities for the six months ended June 30, 2025 was $41.2 million, compared to $43.8 million for the same period in 2024, reflecting a decrease of 6%[163][164] - Net cash used in investing activities increased significantly to $182.2 million in the first half of 2025 from $51.6 million in 2024, primarily due to cash used for purchasing marketable securities[165][166] Debt and Financial Risks - As of June 30, 2025, the company had no debt outstanding, mitigating exposure to interest rate risk[174] - The company does not currently hedge against foreign currency risks, although it has contracts denominated in foreign currencies[175] - A hypothetical 100 basis point change in interest rates would not have a material impact on the company's financial results due to the short-term nature of its investments[173] Accounting and Compliance - The company has not generated any revenue from product sales and does not expect to do so in the foreseeable future[132] - The company has not generated any revenue from product sales to date and does not expect to do so until regulatory approval is obtained[155] - The company has made no material changes to its critical accounting policies and estimates as of June 30, 2025[171] - The company has not engaged in any off-balance sheet arrangements during the reported periods[170] - The company entered into a non-cancellable operating lease for approximately 20,011 rentable square feet of office and laboratory space, with total lease obligations of $614,000 due by the end of 2026[169] - The company has an accumulated deficit of $297.4 million as of June 30, 2025, with significant losses incurred since inception, including net losses of $89.0 million and $71.6 million for the years ended December 31, 2024 and 2023, respectively[126]